@article{oai:kumadai.repo.nii.ac.jp:00026741,
 author = {平島, 浩太郎 and 馬場, 祥史 and 渡邊, 雅之 and 辛島, 龍一 and 佐藤, 伸隆 and 今村, 裕 and 長井, 洋平 and 林, 尚子 and 猪山, 賢一 and 馬場, 秀夫 and Hirashima, Kotaro and 馬場, 祥史 and Baba, Yoshifumi and 渡邊, 雅之 and Watanabe, Masayuki and Karashima, Ryu-ichi and Sato, Nobutaka and Imamura, Yu and Nagai, Yohei and Hayashi, Naoko and Iyama, Ken-ichi and Baba, Hideo},
 issue = {5},
 journal = {British Journal of Cancer},
 month = {Feb},
 note = {application/pdf, application/pdf, application/pdf, application/pdf, 論文(Article), Background: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and homeostasis. The presence and prognostic significance of inappropriate mTOR activation have been reported for several cancers. Mammalian target of rapamycin inhibitors, such as everolimus (RAD001), are in development and show promise as anti-cancer drugs; however, the therapeutic effect of everolimus on oesophageal squamous cell carcinoma (OSCC) remains unknown.
Methods: Phosphorylation of mTOR (p-mTOR) was evaluated in 167 resected OSCC tumours and 5 OSCC cell lines. The effects of everolimus on the OSCC cell lines TE4 and TE11 in vitro and alone or in combination with cisplatin on tumour growth in vivo were evaluated.
Results: Mammalian target of rapamycin phosphorylation was detected in 116 tumours (69.5%) and all the 5 OSCC cell lines. Everolimus suppressed p-mTOR downstream pathways, inhibited proliferation and invasion, and induced apoptosis in both TE4 and TE11 cells. In a mouse xenograft model established with TE4 and TE11 cells, everolimus alone or in combination with cisplatin inhibited tumour growth.
Conclusion: The mTOR pathway was aberrantly activated in most OSCC tumours. Everolimus had a therapeutic effect both as a single agent and in combination with cisplatin. Everolimus could be a useful anti-cancer drug for patients with OSCC., http://www.nature.com/bjc/journal/v106/n5/abs/bjc201236a.html},
 pages = {876--882},
 title = {Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma},
 volume = {106},
 year = {2012},
 yomi = {ババ, ヨシフミ and ワタナベ, マサユキ}
}